Innate Pharma S.A. (IPHA) Earnings History
Net Loss21 years of earnings data (2005–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Innate Pharma S.A. (IPHA) Earnings Overview
As of June 28, 2026, Innate Pharma S.A. (IPHA) reported trailing twelve-month net income of -$98M, reflecting +13.1% year-over-year growth. The company earned $-1.08 per diluted share over the past four quarters, with a net profit margin of -1764.5%.
Looking at the long-term picture, IPHA's historical earnings data spans multiple years. The company achieved its highest annual net income of $13M in fiscal 2016.
Innate Pharma S.A. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), NKTR (-$158M net income, -297.1% margin), CRIS (-$21M net income, -80.3% margin), IPHA has outperformed on profitability metrics. Compare IPHA vs FATE →
IPHA Earnings vs Peers
Earnings metrics vs comparable public companies
IPHA Historical Earnings Data (2005–2025)
21 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$49M | +0.6% | -$53M | $-0.53 | -1764.5% | -1916.9% |
| 2024 | -$49M | -553.5% | -$52M | $-0.61 | -392.0% | -408.6% |
| 2023 | -$8M | +87.0% | -$13M | $-0.09 | -14.6% | -24.4% |
| 2022 | -$58M | -10.0% | -$57M | $-0.73 | -100.7% | -99.6% |
| 2021 | -$53M | +17.5% | -$48M | $-0.57 | -436.0% | -394.9% |
| 2020 | -$64M | -208.2% | $1M | $-0.01 | -91.7% | 1.5% |
| 2019 | -$21M | -780.8% | -$27M | $-0.31 | -30.1% | -39.2% |
| 2018 | $3M | +106.3% | $5M | $0.05 | 3.8% | 6.4% |
| 2017 | -$48M | -482.8% | -$40M | $-0.89 | -148.3% | -122.5% |
| 2016 | $13M | +288.5% | $8M | $0.23 | 22.5% | 13.5% |
| 2015 | -$7M | +65.9% | -$11M | $-0.13 | -37.5% | -60.2% |
| 2014 | -$20M | -579.4% | -$20M | $-0.39 | -2166.2% | -2201.3% |
| 2013 | -$3M | +9.6% | -$3M | $-0.07 | -23.2% | -22.4% |
| 2012 | -$3M | +54.2% | -$3M | $-0.08 | -30.8% | -32.6% |
| 2011 | -$7M | +48.9% | -$8M | $-0.19 | -59.5% | -64.5% |
| 2010 | -$14M | +6.6% | -$14M | $-0.36 | -316.2% | -316.9% |
| 2009 | -$15M | -48.5% | -$16M | $-0.56 | -189.6% | -201.3% |
| 2008 | -$10M | -10.5% | -$11M | $-0.38 | -76.2% | -85.2% |
| 2007 | -$9M | -47.6% | -$9M | $-0.36 | -62.4% | -63.6% |
| 2006 | -$6M | +1.4% | -$7M | $-0.34 | -97.5% | -116.9% |
| 2005 | -$6M | - | -$6M | $-0.41 | -471.5% | -493.5% |
Download Data
Export IPHA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IPHA — Frequently Asked Questions
Quick answers to the most common questions about buying IPHA stock.
What is IPHA earnings per share (EPS)?
IPHA trailing twelve-month (TTM) diluted EPS is $-1.08, reflecting +13.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2025 is available in the table on this page.
What is Innate Pharma S.A.'s net income?
Innate Pharma S.A. (IPHA) trailing twelve-month net income is $-98M as of 2025. Earnings grew +13.1% year-over-year.
Is IPHA profitable?
IPHA is not currently profitable on a TTM basis, reporting a net loss of $-98M. Net margin is -1764.5%. Investors should monitor for a return to profitability.
What is IPHA's earnings growth rate?
IPHA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2025.
What are IPHA's profit margins?
Innate Pharma S.A. net profit margin is -1764.5%, operating margin is -1916.9%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is IPHA growing earnings?
IPHA is growing earnings steadily. YoY EPS growth of +13.1% is consistent with the 5-year CAGR of N/A. TTM net income is $-98M.
What was IPHA's best earnings year?
Innate Pharma S.A.'s highest annual net income on record is $13M, achieved in fiscal year 2016. Earnings history on this page spans 2005 to 2025 and includes all annual and quarterly figures.
What were IPHA's earnings last quarter?
IPHA's most recent reported quarter was Q4 2025. Net income was $-28M with diluted EPS of $-0.30. For a full breakdown of all quarters, see the quarterly earnings table on this page.